Isomorphic Labs pricing

About

Isomorphic Labs is an Alphabet company spun out of Google DeepMind in late 2021, headquartered in London and led by founder and CEO Sir Demis Hassabis — the DeepMind co-founder who shared the 2024 Nobel Prize in Chemistry for AlphaFold. Its mission is to “reimagine the entire drug discovery process from first principles with an AI-first approach,” and its central commercial asset is the Isomorphic Drug Design Engine (IsoDDE) — predictive and generative models built on and beyond AlphaFold 3 (co-released with Google DeepMind in May 2024). In February 2026 the company reported that IsoDDE roughly doubled AlphaFold 3’s performance on a protein-ligand structure-prediction generalization benchmark.

The company ran in near-stealth for years before taking outside capital. It raised its first external round of $600M in March 2025 (led by Thrive Capital, with GV and follow-on from Alphabet), then a $2.1B Series B in May 2026 (Thrive-led, with Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund) — capital aimed at scaling IsoDDE, expanding globally, and progressing its drug-candidate pipeline.

Crucially for a pricing blueprint: Isomorphic Labs publishes no pricing of any kind. The website (isomorphiclabs.com) exposes Our Tech, Partnerships, Articles, and Careers, with a single commercial call-to-action — “Work with us” — routing to partnering@isomorphiclabs.com; isomorphiclabs.com/pricing returns a 404. There is no plan grid, no per-API rate card, and no self-serve checkout. Instead, Isomorphic Labs is paid the way a frontier biotech is paid: upfront cash, R&D/clinical/commercial milestone payments, and tiered royalties on drugs that reach the market. So this page documents what is honestly known — the company, its funding, its disclosed deal terms, and its outcome-based commercial posture — rather than inventing a rate card the company has never published.

Pricing summary : an outcome-based drug-discovery lab with no rate card

Isomorphic Labs runs a partnership-led, outcome-based, no-public-price model. There is no subscription, no published per-API price, and no self-serve tier to evaluate. The dimensions, such as they can be observed from disclosed deals, are:

• Pharma partnership deals — quoted bespoke via “Work with us” (partnering@isomorphiclabs.com). The shape is an upfront payment + R&D/clinical/commercial milestone payments + tiered royalties on net sales of resulting drugs. Disclosed examples: Eli Lilly ($45M upfront, up to $1.7B milestones, plus royalties up to low double digits) and Novartis ($37.5M upfront, up to $1.2B milestones, plus mid-single to low-double-digit royalties), both announced January 2024 — roughly $3B combined biobucks before royalties. A 2025 Johnson & Johnson collaboration followed with undisclosed terms.
• Internal pipeline — around 17 programs across oncology, immunology, and cardiovascular disease, intended to be advanced through early trials and then licensed out. The first AI-designed cancer drug is targeted for Phase 1 by end of 2026. These imply future milestone/royalty value, not a price a buyer can pay today.
• AlphaFold 3 (academic, free) — co-released with Google DeepMind, free for non-commercial academic use via Google Cloud. This is a research artifact, not a product tier — commercial drug design stays behind the partnership conversation.

What makes this different: unlike a SaaS vendor that meters seats or API calls, Isomorphic Labs is paid when science works — a target validated, a candidate advanced, a trial passed, a drug approved and sold. The “value metric” is clinical and commercial progress, which is exactly the kind of thing that resists a public unit price. It is the corpus’s clearest example of outcome-based pricing taken to the pharmaceutical extreme.

Pricing by product

Sales motions across products: fully partnership-led / sales-led for the only revenue-bearing surface (pharma deals, negotiated via “Work with us”). The internal pipeline has no external sales motion (it is the company’s own R&D), and AlphaFold 3’s academic access is a free, self-serve research artifact, not a commercial SKU.

Hidden costs : What an Isomorphic Labs partner actually pays

Because Isomorphic Labs publishes no price, the “real bill” question is fundamentally a deal-structure question — and the costs land in unusual places for anyone used to software pricing.

Path 1 — a pharma partnership. A partner does not “pay a subscription.” Instead the economics unfold over years: an upfront payment at signing, then a ladder of milestone payments triggered as programs hit research, clinical, and commercial gates, and finally royalties as a percentage of net sales if a drug reaches the market. The hidden cost here is time and conditionality — much of the value is contingent on scientific success that may take a decade to materialize, and the headline “up to $1.7B” figure is a ceiling that is only reached if many milestones land. There is no calculator a buyer can self-serve against; everything is in the contract.

Path 2 — the internal pipeline. There is nothing to “buy” here at all today. Isomorphic Labs funds these programs itself (hence the $600M and $2.1B raises) and intends to license them out after early trials — so the “cost” is borne by Isomorphic and its investors now, with value realized later as milestones and royalties from a future licensee.

Want to understand how outcome- and milestone-based economics differ from a software rate card? See understanding usage-based pricing models, and compare how another AI-first drug-discovery peer, Recursion, structures partnership milestones. Isomorphic Labs itself publishes no rate to plug into the Isomorphic Labs pricing calculator.

Pricing evolution : Isomorphic Labs pricing history and changes

Isomorphic Labs has never had a public price to change. Its “pricing evolution” is really a commercial-model evolution: stealth Alphabet spinout, then a string of outcome-based pharma deals that defined its economics, then two large capital raises to fund an internal pipeline — all while keeping any actual numbers behind partnership contracts. The milestones below are reconstructed from primary announcements and a live 2026-06-14 site check.

Cadence

Tracked range: 2024 Q1–2026 Q2. Zero public price changes across the company’s life — there has never been a published rate card to revise; deal terms are set per partnership. Quarters not listed had no relevant public commercial event.

Notable changes

• 2024-01 — Eli Lilly ($45M upfront, up to $1.7B milestones + royalties) and Novartis ($37.5M upfront, up to $1.2B milestones + royalties) multi-target small-molecule deals establish the outcome-based model — roughly $3B combined biobucks before royalties (PR Newswire — Lilly, PR Newswire — Novartis).
• 2025-03 — $600M first external round led by Thrive Capital (with GV and Alphabet); capital to scale IsoDDE and move toward clinical development (isomorphiclabs.com).
• 2025 — Johnson & Johnson (Janssen) multi-modality research collaboration; terms undisclosed (isomorphiclabs.com).
• 2026-05-12 — $2.1B Series B (Thrive-led; Alphabet, GV, MGX, Temasek, CapitalG, UK Sovereign AI Fund); funds the drug-design engine and pipeline progression (isomorphiclabs.com).
• 2026-06-14 — Live check confirms no public pricing: isomorphiclabs.com/pricing 404s; the only commercial CTA is “Work with us” (partnering@isomorphiclabs.com).

What’s unique : Isomorphic Labs’s distinctive pricing mechanics

1. The meter is a molecule, not an API call. Where almost every AI company in this corpus meters tokens, seats, or compute, Isomorphic Labs gets paid when drug programs hit milestones and when approved drugs sell. The revenue event is a target validated, a candidate advanced, a trial passed — scientific progress measured over years, not consumption measured in real time. That is the purest form of outcome-based pricing in the dataset: the customer (a pharma partner) underwrites the result, not the software.

2. Ceilings, not list prices. The numbers Isomorphic Labs does disclose — “$45M upfront, up to $1.7B in milestones” — are deal ceilings, not prices anyone pays up front. Most of that headline value is contingent on a ladder of milestones that may never all be reached. This conditional, back-loaded structure is the opposite of a SaaS rate card, and it deliberately aligns Isomorphic’s upside with its partners’ clinical success rather than with usage volume.

3. A platform that also runs its own pipeline. Unlike a pure tools vendor, Isomorphic Labs both licenses its engine to partners and develops its own drugs (~17 internal programs) that it intends to license out after early trials. It is simultaneously a picks-and-shovels supplier and a prospector — so its “pricing” spans partner milestone deals and future royalties on drugs it discovers itself. (For how to choose a value metric when the deliverable is an outcome rather than a unit, see choosing the right usage metric.)

Strengths & weaknesses

Billing UX : Isomorphic Labs billing controls and transparency

• Billing controls — None are public. There is no self-serve dashboard, no usage meter, and no plan-management UI; commercial terms are handled entirely through partnership contracts negotiated via partnering@isomorphiclabs.com.
• Usage visibility — Not applicable. The “usage” being paid for is scientific and clinical progress, tracked through joint research programs and milestone definitions in the contract, not through an API console.
• Payment options — Not disclosed publicly. Deals are structured as upfront payments, milestone payments, and royalties under bespoke partnership agreements; there is no card checkout or billing portal.
• Transparency — Deliberately low on the commercial side (no rate card; only deal-level figures surface via partner press releases and partners’ regulatory filings) and high on the scientific side (the company publishes research and co-released AlphaFold 3 for academic use).

Strategic wins : Why Isomorphic Labs’s pricing decisions worked

1. Milestone + royalty deals turn a model into a drug-development business

By structuring partnerships as upfront + milestones + royalties, Isomorphic Labs converted “we have a great AI model” into durable, multi-year, multi-billion-dollar commercial relationships with Eli Lilly and Novartis. This aligns its revenue with partners’ clinical success rather than with usage volume — a defensible stance when the deliverable is a drug, not a token. It mirrors how other AI companies are rethinking what they meter.

2. No list price, no commoditization

For a lab selling bespoke, high-stakes co-development, publishing a rate card would invite reductive comparison with cheaper computational-chemistry tools. By negotiating every collaboration, Isomorphic Labs keeps pricing tied to delivered scientific value and protects its leverage — a sensible posture when each deal is a unique, target-specific program rather than a fungible SKU. See usage-based pricing strategy for when metering the outcome beats metering the unit.

3. Pedigree and capital as the on-ramp

With a Nobel laureate at the helm, AlphaFold 3 lineage, and Alphabet plus sovereign funds on the cap table, Isomorphic Labs can lead pharma conversations with scientific credibility rather than a price-performance table — and its $600M and $2.1B raises buy the runway to fund an internal pipeline that compounds future milestone/royalty value. That capital depth is itself a strategic moat in a field where results take a decade.

Areas to improve : Gaps in Isomorphic Labs’s pricing approach

1. The economics are opaque to everyone outside a deal

Because terms surface only through partner press releases and partners’ regulatory filings, the broader market can’t see how Isomorphic prices risk or structures milestones. That opacity is defensible for bespoke pharma deals, but it makes the company hard to evaluate, benchmark, or learn from. Even a high-level framework for how it structures partnerships would reduce friction for prospective collaborators. The total opacity invites exactly the cost-unpredictability anxiety that slows enterprise commitments.

2. No on-ramp below a full pharma partnership

There is no smaller, lower-commitment way to engage — no priced “platform access,” no developer tier, no scoped pilot SKU. That keeps Isomorphic Labs accessible only to large pharma, foreclosing relationships with biotechs that might grow into bigger collaborations. A staged, partly transparent entry point could widen the funnel without giving up the bespoke high end.

3. Value is back-loaded and unproven

The model only fully pays off if molecules survive the clinic — and the first internal candidate is only targeted for Phase 1 by end of 2026, with no approved drug yet. Until milestones convert to royalties, the headline “up to $X billion” figures remain ceilings rather than revenue. More public clarity on which gates have actually been reached would make the economics more legible.

Key takeaways

1. No public price is itself a pricing decision. Isomorphic Labs publishes zero commercial pricing and routes everything through “Work with us” — a deliberate, partnership-led posture for bespoke, high-value drug-development deals where a rate card would only commoditize the offering.
2. The meter is scientific progress, not consumption. Revenue arrives as upfronts, milestone payments, and royalties tied to drug programs advancing — the purest outcome-based model in the corpus. The customer underwrites the result, not the software.
3. Disclosed figures are ceilings, not prices. “$45M upfront, up to $1.7B milestones” describes a contingent ladder, most of which is only reached if many gates pass over years — fundamentally different from a SaaS subscription.
4. It is both a platform and a pipeline. Isomorphic Labs licenses its engine to pharma and develops its own ~17 programs to license out — giving it multiple paths to milestone/royalty upside, but also a long, capital-intensive road before revenue compounds.
5. Pedigree and deep capital substitute for a rate card. Nobel-laureate leadership, AlphaFold 3 lineage, and $600M-then-$2.1B raises let Isomorphic sell on scientific credibility and fund a decade-long R&D cycle — viable precisely because the offering is a custom outcome, not a commodity unit.

UBP implications

1. Some value is best metered by the outcome, not the unit. When the deliverable is a working drug rather than a fungible API call, an outcome-based structure (upfront + milestones + royalties) aligns incentives far better than a usage meter. UBP practitioners should match the meter to what the buyer actually values — here, clinical and commercial success.
2. Ceilings and contingency are pricing tools, not just legal terms. Isomorphic’s “up to $X” milestone ladders let it advertise large potential value while only collecting as risk is retired. UBP designers building outcome models should be explicit about which events trigger payment, because the structure of contingency is the price.
3. Opacity protects bespoke value — but limits the funnel. Refusing to publish a rate card shields a high-stakes, custom offering from commoditization, yet it also locks out everyone who can’t enter a full partnership. The lesson: decide deliberately where transparency widens the funnel and where it merely erodes leverage.

Sources

• Isomorphic Labs — official site (no pricing page; “Work with us” CTA) (accessed 2026-06-14)
• Isomorphic Labs — Our Tech (Isomorphic Drug Design Engine) (accessed 2026-06-14)
• Isomorphic Labs — strategic collaboration with Eli Lilly ($45M upfront, up to $1.7B milestones + royalties) (accessed 2026-06-14)
• Isomorphic Labs — strategic collaboration with Novartis ($37.5M upfront, up to $1.2B milestones + royalties) (accessed 2026-06-14)
• Isomorphic Labs kicks off 2024 with two pharma deals (~$3B combined potential) — Irish Pharmacist (accessed 2026-06-14)
• Isomorphic Labs — Johnson & Johnson research collaboration (terms undisclosed) (accessed 2026-06-14)
• Isomorphic Labs — $600M first external investment round (March 2025) (accessed 2026-06-14)
• Isomorphic Labs — $2.1B Series B (May 2026) (accessed 2026-06-14)
• Inside Isomorphic Labs, the DeepMind life-sciences spinoff (CNBC) (accessed 2026-06-14)
• Alphabet-backed Isomorphic Labs raises $2.1B as clinical trials near (Tech Startups) (accessed 2026-06-14)
• Browse the pricing blueprint corpus

Bottom line

Isomorphic Labs is the corpus’s clearest example of outcome-based pricing pushed to the pharmaceutical extreme: an Alphabet/DeepMind spinout led by Nobel laureate Demis Hassabis that commercializes AlphaFold 3 through its Isomorphic Drug Design Engine — and publishes no price for any of it. isomorphiclabs.com/pricing is a literal 404, and the only commercial path is “Work with us.” It is paid not by a subscription but by pharma deals structured as upfront cash + R&D/commercial milestones + royalties: Eli Lilly ($45M upfront, up to $1.7B) and Novartis ($37.5M upfront, up to $1.2B) alone carry ~$3B in combined milestone potential, with a 2025 Johnson & Johnson deal at undisclosed terms. Backed by $600M then a $2.1B Series B, it is also building ~17 internal programs to license out — with its first AI-designed cancer drug targeted for Phase 1 by end of 2026. The meter here is a molecule that works, not an API call.

Want to compare Isomorphic Labs against other AI-first drug-discovery and outcome-priced peers? See Recursion, read about usage-based pricing models, or browse the full pricing blueprint.